Olmesartan medoxomil-d6 is intended for use as an internal standard for the quantification of olmesartan medoxomil by GC- or LC-MS. Olmesartan medoxomil is an orally bioavailable prodrug form of olmesartan , a nonpeptide angiotensin II antagonist that is selective for the angiotensin 1 (AT1) receptor over the AT2 receptor.1 Olmesartan medoxomil (0.1 mg/kg) inhibits the angiotensin II pressor response in normotensive rats. It reduces both systolic and diastolic blood pressure in fructose-fed rats, a model of insulin resistance, when administered at a dose of 10 mg/kg per day, as well as in chow-fed control animals when administered at a dose of 11.4 mg/kg per day.2 Olmesartan medoxomil also inhibits increases in plasma levels of triglycerides and non-esterified fatty acids in fructose-fed rats. Formulations containing olmesartan medoxomil have been used in the treatment of hypertension.
1.Mizuno, M., Sada, T., Ikeda, M., et al.Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonistEur. J. Pharmacol.285(2)181-188(1995) 2.Okada, K., Hirano, T., Ran, J., et al.Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed ratsHypertens. Res.27(4)293-299(2004)